Cencora Enhances Global Pharmaceutical Logistics Services And Cold Chain Capabilities

Expanded capacity in Europe and the US enables the company to deliver enhanced third-party logistics support to pharmaceutical companies

Cencora, a global pharmaceutical solutions company, today announced investments to enhance its third-party logistics (3PL) capabilities in the United States and Europe, expand its global network and strengthen the specialty logistics services it can provide to pharmaceutical companies worldwide.

As more specialty pharmaceuticals reach the market and the demand for comprehensive pharmaceutical supply management continues to increase, Cencora is enhancing its global 3PL service offering by:

• Increasing capacity in key European markets : Cencora is expanding its pan-European logistics capabilities through NextPharma Logistics, a healthcare logistics provider that provides services across Germany, Austria and Switzerland. Cencora will also open a 3PL facility in Italy in 2026, building on recent investments to expand warehousing capacity in France, Spain and the UK.
• Expansion of storage capacity, cold chain capacity in the US : Cencora plans to open a new, highly automated 500,000-square-foot 3PL facility in Texas in 2028.

“Our customers trust us to act as an extension of their business. We continue to strengthen our pharmaceutical logistics capabilities through investments across our 3PL network to deliver enhanced support tailored to their needs,” said Chris Williams, Senior Vice President and President of Alloga Europe & ICS . “Whether it’s a large-scale global program or supporting the launch of an advanced treatment in a new market, we are able to provide the integrated support our customers need to navigate the complexities of the supply chain, maximize commercial success, and ensure efficient and reliable access to their products.”

Enhanced pan-European 3PL capabilities
Headquartered in Germany, NextPharma Logistics offers integrated supply chain solutions, such as warehousing, distribution, serialization, and quality assurance and compliance management. The company offers temperature-controlled solutions, including refrigerated and deep-frozen storage, through its Good Distribution Practice (GDP)-compliant facilities in Germany, Austria, and Switzerland.

The addition of NextPharma Logistics and the planned opening of a 3PL facility in Italy increases Cencora’s logistics capabilities in key markets in Europe, enabling the company to provide more comprehensive pan-European support. Cencora is further strengthening its specialty logistics in Europe by expanding cold chain capacity across the network, including the development of a dedicated specialty unit equipped with cryogenic technology in the Netherlands and the increase in refrigerated and frozen storage capacity in France.

“Pharmaceutical companies are increasingly looking for partners who can provide comprehensive support across multiple markets,” said Alina Chesnokova, Vice President, Global 3PL Commercialization, Cencora . “Through our internationally scaled 3PL service and suite of commercialization solutions, Cencora is uniquely positioned to support their needs, delivering integrated support to enable seamless expansion into new markets and ensure products are delivered on time and in the right condition.”

Expanded capacity, cold chain capacity in the US
Cencora plans to open a 500,000-square-foot 3PL facility in Texas, which is expected to be fully operational in 2028. The new facility – Cencora’s fifth 3PL facility in the United States – will increase Cencora’s capacity to store products at controlled room temperature, refrigerated and frozen ranges, including ultra-low and cryogenic.

In addition to the Texas facility, Cencora has more than tripled its ultra-low and cryogenic storage capacity across its 3PL network in the U.S. to support the growing number of specialty medicines, such as cell and gene therapies. The expanded storage capacity, combined with Cencora’s global specialty logistics capabilities , enables the company to offer comprehensive logistics support from clinical trials to commercialization, including a supply chain solution designed for cell and gene therapies.

For more information, visit Cencora.com/logistics/3PL.